Mauna Kea Technologies SAEURONEXT: ALMKT

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

· Issued by Mauna Kea Technologies SA via Business Wire

Summary by 6ix AI

Mauna Kea Technologies, maker of the Cellvizio medical imaging platform, will host a webinar for shareholders and the financial community on Tuesday, July 21, 2026 at 5:50 pm CEST to discuss key highlights of the first half of 2026.

Key details

  • Chairman and CEO Sacha Loiseau and Chief Financial Officer Côme de La Tour du Pin will give live commentary, followed by a question-and-answer session.
  • The session will be held in French; advance registration is required, and a replay will be available to registered participants.
  • Mauna Kea Technologies is listed on Euronext Growth under the ticker ALMKT.

6ix AI wrote this summary from the release below and checked it against the release.

PARIS & BOSTON, July 16, 2026--(BUSINESS WIRE)--Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.

Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.

Advance registration is required to participate in the event.

Webinar for shareholders and investors – Tuesday, July 21 2026

5:50 pm. (CEST) – French Session: Click here to register

A replay will be available for registered participants.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716753144/en/

Contacts

Mauna Kea Technologies
[email protected]

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
[email protected]

View original source (Business Wire)Mauna Kea Technologies SA on 6ix

Earlier from Mauna Kea Technologies

Later from Mauna Kea Technologies

All Mauna Kea Technologies news releases